• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Successful Treatment of Interstitial Lung Disease in STAT3 Gain-of-Function Using JAK Inhibitors.

作者信息

Silva-Carmona Manuel, Vogel Tiphanie P, Marchal Sarah, Guesmi Myriam, Dubus Jean-Christophe, Leroy Sylvie, Fabre Alexandre, Barlogis Vincent, Forbes Lisa R, Giovannini-Chami Lisa

机构信息

Texas Children's Hospital Houston, Texas.

Baylor College of Medicine Houston, Texas.

出版信息

Am J Respir Crit Care Med. 2020 Sep 15;202(6):893-897. doi: 10.1164/rccm.201906-1204LE.

DOI:10.1164/rccm.201906-1204LE
PMID:32392079
Abstract
摘要

相似文献

1
Successful Treatment of Interstitial Lung Disease in STAT3 Gain-of-Function Using JAK Inhibitors.使用JAK抑制剂成功治疗STAT3功能获得性突变所致间质性肺疾病
Am J Respir Crit Care Med. 2020 Sep 15;202(6):893-897. doi: 10.1164/rccm.201906-1204LE.
2
STAT3 Gain of Function: A New Kid on the Block in Interstitial Lung Diseases.信号转导与转录激活因子3功能获得：间质性肺疾病领域的新成员
Am J Respir Crit Care Med. 2018 Jun 1;197(11):e22-e23. doi: 10.1164/rccm.201707-1500IM.
3
Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome.Janus 激酶抑制剂治疗 SAVI 综合征的疗效和不良事件。
J Clin Immunol. 2019 Jul;39(5):476-485. doi: 10.1007/s10875-019-00645-0. Epub 2019 May 29.
4
STAT1 Gain of Function, Type 1 Diabetes, and Reversal with JAK Inhibition.信号转导与转录激活因子1功能获得、1型糖尿病以及JAK抑制的逆转作用
N Engl J Med. 2020 Oct 8;383(15):1494-1496. doi: 10.1056/NEJMc2022226.
5
Baricitinib experience on STING-associated vasculopathy with onset in infancy: A representative case from Turkey.巴利昔替尼治疗婴儿期起病的 STING 相关性血管病：土耳其的一个代表性病例。
Clin Immunol. 2020 Mar;212:108273. doi: 10.1016/j.clim.2019.108273. Epub 2019 Oct 15.
6
A Novel Gain-of-Function Mutation in Fatal Infancy-Onset Interstitial Lung Disease.一种新的致致命婴儿期起病的间质性肺病的功能获得性突变。
Front Immunol. 2022 May 23;13:866638. doi: 10.3389/fimmu.2022.866638. eCollection 2022.
7
Early-onset, fatal interstitial lung disease in STAT3 gain-of-function patients.STAT3 功能获得性突变患者的早发型致死性肺间质疾病。
Pediatr Pulmonol. 2021 Dec;56(12):3934-3941. doi: 10.1002/ppul.25684. Epub 2021 Sep 28.
8
JAK inhibitors to treat STAT3 gain-of-function: a single-center report and literature review.JAK 抑制剂治疗 STAT3 功能获得性突变：一项单中心报告及文献复习。
Front Immunol. 2024 Aug 23;15:1400348. doi: 10.3389/fimmu.2024.1400348. eCollection 2024.
9
Pulmonary Histopathology Findings in Patients With STAT3 Gain of Function Syndrome.STAT3 功能获得性综合征患者的肺部组织病理学表现。
Pediatr Dev Pathol. 2021 May-Jun;24(3):227-234. doi: 10.1177/1093526620980615. Epub 2021 Mar 2.
10
STAT3 gain of function: a new aetiology of severe rheumatic disease.信号转导和转录激活因子3功能获得：严重风湿性疾病的一种新病因
Rheumatology (Oxford). 2019 Feb 1;58(2):365-367. doi: 10.1093/rheumatology/key308.

引用本文的文献

1
Successful anti-IL-6 treatment for interstitial lung disease associated with STAT3 gain-of-function: a case report and literature review.成功使用抗白细胞介素-6治疗与信号转导和转录激活因子3功能获得相关的间质性肺病：一例报告及文献综述
Front Pediatr. 2025 Jul 9;13:1577746. doi: 10.3389/fped.2025.1577746. eCollection 2025.
2
Inborn errors of regulatory T-cell differentiation and function.调节性T细胞分化和功能的先天性缺陷。
J Allergy Clin Immunol. 2025 Jul 7. doi: 10.1016/j.jaci.2025.07.001.
3
Mechanism of Shi-Yang-Xiao lotion in alleviating perianal eczema based on network pharmacology and experimental validation.
基于网络药理学和实验验证的湿痒消洗剂缓解肛周湿疹的作用机制
Front Mol Biosci. 2025 Jun 19;12:1621398. doi: 10.3389/fmolb.2025.1621398. eCollection 2025.
4
Case report: JAK inhibitor treatment of immune dysregulation symptoms in a patient with PTPN2 deficiency.病例报告：JAK抑制剂治疗PTPN2缺乏症患者免疫失调症状
Front Immunol. 2025 Jan 31;15:1523256. doi: 10.3389/fimmu.2024.1523256. eCollection 2024.
5
Case report: Successful use of ruxolitinib to treat interstitial pneumonia as an unusual primary presentation in primary myelofibrosis-two birds with one stone.病例报告：成功使用鲁索替尼治疗原发性骨髓纤维化中作为不寻常首发表现的间质性肺炎——一举两得。
Front Oncol. 2024 Nov 26;14:1475036. doi: 10.3389/fonc.2024.1475036. eCollection 2024.
6
What Is on the Horizon for Treatments in Idiopathic Pulmonary Fibrosis?特发性肺纤维化治疗的未来发展趋势如何？
J Clin Med. 2024 Oct 22;13(21):6304. doi: 10.3390/jcm13216304.
7
STAT1 and STAT3 gain of function: clinically heterogenous immune regulatory disorders.STAT1 和 STAT3 获得性功能：临床异质性免疫调节紊乱。
Curr Opin Allergy Clin Immunol. 2024 Dec 1;24(6):440-447. doi: 10.1097/ACI.0000000000001039. Epub 2024 Oct 17.
8
Novel germline STAT3 gain-of-function mutation causes autoimmune diseases and severe growth failure.新型种系 STAT3 功能获得性突变导致自身免疫性疾病和严重生长发育迟缓。
J Allergy Clin Immunol Glob. 2024 Jul 26;3(4):100312. doi: 10.1016/j.jacig.2024.100312. eCollection 2024 Nov.
9
JAK inhibitors to treat STAT3 gain-of-function: a single-center report and literature review.JAK 抑制剂治疗 STAT3 功能获得性突变：一项单中心报告及文献复习。
Front Immunol. 2024 Aug 23;15:1400348. doi: 10.3389/fimmu.2024.1400348. eCollection 2024.
10
A human STAT3 gain-of-function variant drives local Th17 dysregulation and skin inflammation in mice.人类 STAT3 功能获得性变异可导致小鼠局部 Th17 失调和皮肤炎症。
J Exp Med. 2024 Aug 5;221(8). doi: 10.1084/jem.20232091. Epub 2024 Jun 11.